Cargando…

Evaluation of similar quality attribute characteristics in SB5 and reference product of adalimumab

Biosimilars are biologic products that are highly similar to a licensed reference product in terms of quality, safety, and efficacy. SB5 is a biosimilar of Humira® (adalimumab) developed by Samsung Bioepis. To demonstrate its biosimilarity in quality to Humira®, we performed a comprehensive characte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Nayoung, Lee, JongAh Joanne, Yang, Hahymn, Baek, Serim, Kim, Soohwan, Kim, Sooshin, Lee, Tongkeun, Song, Dami, Park, Gwangmin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2018
Materias:	Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343792/ https://www.ncbi.nlm.nih.gov/pubmed/30296198 http://dx.doi.org/10.1080/19420862.2018.1530920

Ejemplares similares

Consistency of Product Quality for SB5, an Adalimumab Biosimilar
por: Lee, JongAh Joanne, et al.
Publicado: (2023)

Physicochemical and biological similarity assessment of LBAL, a biosimilar to adalimumab reference product (Humira®)
por: Kwon, Joon-Cheol, et al.
Publicado: (2021)

Switching From Reference Adalimumab to SB5 (Adalimumab Biosimilar) in Patients With Rheumatoid Arthritis: Fifty‐Two–Week Phase III Randomized Study Results
por: Weinblatt, Michael E., et al.
Publicado: (2018)

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate‐to‐Severe Rheumatoid Arthritis
por: Weinblatt, Michael E., et al.
Publicado: (2017)

Adalimumab biosimilars, ABP501 and SB5, are equally effective and safe as adalimumab originator
por: Cingolani, Linda, et al.
Publicado: (2021)

Biological Characterization of SB3, a Trastuzumab Biosimilar, and the Influence of Changes in Reference Product Characteristics on the Similarity Assessment
por: Lee, Jae Hee, et al.
Publicado: (2019)

Evaluation of the structural, physicochemical, and biological characteristics of SB4, a biosimilar of etanercept
por: Cho, Ick Hyun, et al.
Publicado: (2016)

A Randomized Pharmacokinetic Study in Healthy Male Subjects Comparing a High-concentration, Citrate-free SB5 Formulation (40 mg/0.4 ml) and Prior SB5 (Adalimumab Biosimilar)
por: Ahn, So-shin, et al.
Publicado: (2022)

Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
por: Jiang, Yijia, et al.
Publicado: (2023)

Population pharmacokinetics of adalimumab biosimilar adalimumab‐adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity
por: Kang, Jia, et al.
Publicado: (2020)

Characterization for the Similarity Assessment between Proposed Biosimilar SB12 and Eculizumab Reference Product Using a State-of-the-Art Analytical Method
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Comparative pharmacokinetics of an adalimumab biosimilar SB5 administered via autoinjector or prefilled syringe in healthy subjects
por: Shin, Donghoon, et al.
Publicado: (2018)

Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®
por: Lee, Changsoo, et al.
Publicado: (2017)

Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)
por: Tebbey, Paul W, et al.
Publicado: (2015)

Frequency of peripheral diseases in Korean patients with ankylosing spondylitis and the effectiveness of adalimumab
por: Lee, Sang‐Hoon, et al.
Publicado: (2020)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

Analytical similarity assessment of rituximab biosimilar CT-P10 to reference medicinal product
por: Lee, Kyoung Hoon, et al.
Publicado: (2018)

Demonstration of Functional Similarity of Proposed Biosimilar ABP 501 to Adalimumab
por: Velayudhan, Jyoti, et al.
Publicado: (2016)

Extensive Nevus Comedonicus with Inflammatory Nodules and Cysts Controlled with Adalimumab
por: Lee, Eun Hye, et al.
Publicado: (2021)

Treatment of Hidradenitis Suppurativa Patient with Klinefelter Syndrome by Adalimumab
por: Shin, Ji Yeoun, et al.
Publicado: (2019)

PB2051: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC/EFFICACY MODELING OF SB12 (PROPOSED ECULIZUMAB BIOSIMILAR) AND REFERENCE ECULIZUMAB
por: Lee, Hyuna, et al.
Publicado: (2023)

Survival analysis of implants after surgical treatment of peri-implantitis based on bone loss severity and surgical technique: a retrospective study
por: Hwang, Sooshin, et al.
Publicado: (2023)

Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)

Assessing Analytical Similarity of Proposed Amgen Biosimilar ABP 501 to Adalimumab
por: Liu, Jennifer, et al.
Publicado: (2016)

SB5 shows cross-immunogenicity to adalimumab but not infliximab: results in patients with inflammatory bowel disease or rheumatoid arthritis
por: Goncalves, Joao, et al.
Publicado: (2019)

Fidelity assessment of the suicide reporting guidelines in Korean newspapers
por: Chun, JongSerl, et al.
Publicado: (2018)

An International Systematic Review of Prevalence, Risk, and Protective Factors Associated with Young People’s E-Cigarette Use
por: Kim, Jinyung, et al.
Publicado: (2022)

The PROPER Study: A 48-Week, Pan-European, Real-World Study of Biosimilar SB5 Following Transition from Reference Adalimumab in Patients with Immune‐Mediated Inflammatory Disease
por: Müller-Ladner, Ulf, et al.
Publicado: (2023)

Investigation of the Effect of Double-Filler Atoms on the Thermoelectric Properties of Ce-YbCo(4)Sb(12)
por: Binh, Nguyen Vu, et al.
Publicado: (2023)

The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
por: Park, Sung Eun, et al.
Publicado: (2021)

Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature
por: Park, Dongkuk, et al.
Publicado: (2018)

A randomized phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel®) in healthy subjects
por: Lee, Yoon Jung, et al.
Publicado: (2016)

CODA-ML: context-specific biological knowledge representation for systemic physiology analysis
por: Kwon, Mijin, et al.
Publicado: (2019)

Health-related Quality of Life Outcomes of Adalimumab for Patients With Rheumatoid Arthritis in Korea
por: Lee, Myeung-su, et al.
Publicado: (2021)

Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
por: Sohn, Il Woong, et al.
Publicado: (2016)

Evaluation of analytical similarity between trastuzumab biosimilar CT-P6 and reference product using statistical analyses
por: Lee, Jihun, et al.
Publicado: (2018)

Distinct alterations of fecal microbiota refer to the efficacy of adalimumab in Crohn’s disease
por: Chen, Liang, et al.
Publicado: (2022)

A Social-Ecological Approach to Understanding the Relationship between Cyberbullying Victimization and Suicidal Ideation in South Korean Adolescents: The Moderating Effect of School Connectedness
por: Lee, Jungup, et al.
Publicado: (2021)

Elution of Labile Fluorescent Dye from Nanoparticles during Biological Use
por: Tenuta, Tiziana, et al.
Publicado: (2011)

A Word Pair Dataset for Semantic Similarity and Relatedness in Korean Medical Vocabulary: Reference Development and Validation
por: Yum, Yunjin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_edth7l5l7nrd2api9b90531o4j